Debbie Dumont
Co-founder and Managing Partner @ Bioqube Ventures
San Francisco, United States
Debbie Dumont is a Series A investor at Bioqube Ventures in San Francisco focused on Biotechnology and Health Care. Debbie Dumont
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Debbie Dumont invests in
Stages Debbie Dumont invests in
Countries Debbie Dumont invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Medical 1 (25%)
- Life Science 1 (25%)
- Therapeutics 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Series B 1 (25%)
Country
- United States 2 (50%)
- Norway 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $23.3M / Series B / Jan 26, 2026 | |
|
|
Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M / Series A / Jul 09, 2025 | |
|
|
Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $4M / Series A / Jan 12, 2021 | |
|
|
Enhanc3D Genomics is a spinout company from Babraham Institute. | Seed / Jan 01, 2021 |
Co-Investors
About Bioqube Ventures
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Bioqube Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Debbie Dumont
Co-founder and Managing Partner
|
|||
|
Debora Dumont
Co-Founder & Managing Partner
|
|||
|
Dirk Reyn
Managing Partner
|
|||
|
Nico Vandervelpen
Co-founder and Managing Partner
|
|||
|
Tom Heyman
Executive Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Debbie Dumont invest in?
Debbie Dumont invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Debbie Dumont last invest?
The most recent investment recorded for Debbie Dumont closed in Jan 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!